OBJECTIVE: To understand factors driving the economic burden of major depressive disorder (MDD) patients with different treatment regimens, by evaluating the relationship between medical profiles and treatment costs. METHODS: Claims data for US privately insured employees (1999-2004) were analysed. Analysis included adult employees with >/=1 diagnosis of MDD and >/=1 prescription for specific antidepressants following a 6-month washout period. Patients were first classified into treatment pattern groups (switchers/discontinuers/maintainers/augmenters), then stratified into mutually exclusive treatment groups - nonstable, stable and intermediate - based on evidence of stability in treatment therapy. Rates of mental and physical co-morbidities, injuries/accidents, substance abuse and urgent care use were analysed across treatment pattern groups. Direct (medical/drug) costs were calculated per patient per year and disaggregated into depression- and non-depression-related components. A two-part multivariate model controlled for baseline characteristics. Costs were also estimated for patients with MDD only, patients with MDD and generalized anxiety disorder (GAD), and patients with MDD and any type of anxiety. RESULTS: Annual per patient adjusted costs (year 2005 values) were significantly lower among stable patients ($US6215) than among intermediate ($US7317) and nonstable patients ($US9948; p < 0.001). Stable patients also had lower depression- and non-depression-related costs. Patients with MDD and comorbid GAD or any type of anxiety had significantly higher costs than MDD-only patients. CONCLUSIONS: Nonstability of treatment is associated with higher comorbidity rates, more urgent care use and higher total, depression- and non-depression-related direct costs. The stable group represents continuity of care and is associated with significant cost savings. Co-morbidities are associated with increased costs.
OBJECTIVE: To understand factors driving the economic burden of major depressive disorder (MDD) patients with different treatment regimens, by evaluating the relationship between medical profiles and treatment costs. METHODS: Claims data for US privately insured employees (1999-2004) were analysed. Analysis included adult employees with >/=1 diagnosis of MDD and >/=1 prescription for specific antidepressants following a 6-month washout period. Patients were first classified into treatment pattern groups (switchers/discontinuers/maintainers/augmenters), then stratified into mutually exclusive treatment groups - nonstable, stable and intermediate - based on evidence of stability in treatment therapy. Rates of mental and physical co-morbidities, injuries/accidents, substance abuse and urgent care use were analysed across treatment pattern groups. Direct (medical/drug) costs were calculated per patient per year and disaggregated into depression- and non-depression-related components. A two-part multivariate model controlled for baseline characteristics. Costs were also estimated for patients with MDD only, patients with MDD and generalized anxiety disorder (GAD), and patients with MDD and any type of anxiety. RESULTS: Annual per patient adjusted costs (year 2005 values) were significantly lower among stable patients ($US6215) than among intermediate ($US7317) and nonstable patients ($US9948; p < 0.001). Stable patients also had lower depression- and non-depression-related costs. Patients with MDD and comorbid GAD or any type of anxiety had significantly higher costs than MDD-only patients. CONCLUSIONS: Nonstability of treatment is associated with higher comorbidity rates, more urgent care use and higher total, depression- and non-depression-related direct costs. The stable group represents continuity of care and is associated with significant cost savings. Co-morbidities are associated with increased costs.
Authors: Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112
Authors: Christopher Ron Cantrell; Michael T Eaddy; Manan B Shah; Timothy S Regan; Michael C Sokol Journal: Med Care Date: 2006-04 Impact factor: 2.983
Authors: G E Simon; D Revicki; J Heiligenstein; L Grothaus; M VonKorff; W J Katon; T R Hylan Journal: Gen Hosp Psychiatry Date: 2000 May-Jun Impact factor: 3.238
Authors: Howard Birnbaum; Paul E Greenberg; Jackson Tang; Matthew Hsieh; Eric Q Wu; Caroline Amand; Rym Ben-Hamadi Journal: J Med Econ Date: 2009-03 Impact factor: 2.448
Authors: Paul Greenberg; Patricia K Corey-Lisle; Howard Birnbaum; Maryna Marynchenko; Ami Claxton Journal: Pharmacoeconomics Date: 2004 Impact factor: 4.981
Authors: James M Russell; Kevin Hawkins; Ronald J Ozminkowski; Lucinda Orsini; William H Crown; Sean Kennedy; Stan Finkelstein; Ernst Berndt; A John Rush Journal: J Clin Psychiatry Date: 2004-03 Impact factor: 4.384
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Patricia K Corey-Lisle; Howard G Birnbaum; Paul E Greenberg; Maryna B Marynchenko; Ami J Claxton Journal: J Clin Psychiatry Date: 2002-08 Impact factor: 4.384
Authors: Cynthia L Leibson; Allen W Brown; Kirsten Hall Long; Jeanine E Ransom; Jay Mandrekar; Turner M Osler; James F Malec Journal: J Neurotrauma Date: 2012-04-26 Impact factor: 5.269
Authors: Kevin P Cohoon; Cynthia L Leibson; Jeanine E Ransom; Aneel A Ashrani; Myung S Park; Tanya M Petterson; Kirsten Hall Long; Kent R Bailey; John A Heit Journal: Surgery Date: 2015-01-26 Impact factor: 3.982
Authors: Kevin P Cohoon; Jeanine E Ransom; Cynthia L Leibson; Aneel A Ashrani; Tanya M Petterson; Kirsten Hall Long; Kent R Bailey; John A Heit Journal: Am J Med Date: 2016-03-21 Impact factor: 4.965
Authors: Cynthia L Leibson; Kirsten Hall Long; Jeanine E Ransom; Rosebud O Roberts; Steven L Hass; Amy M Duhig; Carin Y Smith; Jane A Emerson; V Shane Pankratz; Ronald C Petersen Journal: Alzheimers Dement Date: 2015-04-06 Impact factor: 21.566
Authors: Barbara Nussbaumer; Laura C Morgan; Ursula Reichenpfader; Amy Greenblatt; Richard A Hansen; Megan Van Noord; Linda Lux; Bradley N Gaynes; Gerald Gartlehner Journal: CNS Drugs Date: 2014-08 Impact factor: 5.749
Authors: Kevin P Cohoon; Cynthia L Leibson; Jeanine E Ransom; Aneel A Ashrani; Tanya M Petterson; Kirsten Hall Long; Kent R Bailey; Johm A Heit Journal: Am J Manag Care Date: 2015-04-01 Impact factor: 2.229